IN
InMed Pharmaceuticals Inc.
INM · NASDAQ
$1.39 -5.12% (-$0.08)
1M -11.11%
Market Cap $2.32M
P/E Ratio 0.00x
Div. Yield -
ROE 191.57%
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S 0.00x
P/B 0.00x
P/E 0.00x
Growth
100 /100
Growing Book val. growth 306.40%
Rev. growth 815.81%
FCF growth N/A
Profitability
53 /100
Moderate Net margin 25.83%
Op. margin 25.20%
FCF margin 341.77%
Quality
94 /100
Excellent ROE 191.57%
ROA 17.56%
Asset turnover 0.68x
Debt
93 /100
Low Current ratio 1.37x
Net debt/EBITDA -4.68x
Debt/Equity 0.00x
Stability
48 /100
Moderate Rev. volatility 37,041.61%
EPS volatility 21.58%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na INM
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Eric A. Adams Chem.
Employees
13
Headquarters
Vancouver
Nadcházející události
23 ZÁŘ
Earnings
Upcoming earnings report
05 LIS
Earnings
Upcoming earnings report